Biotech Values

[Cactus Quave]

If a Minor Deficiency letter indicates that the FDA views T-Enox as approvable in its current form, this raises the stakes of MNTA's patent infringement claim against TEVA. If TEVA's application is based on a drug that infringes on Momenta's patents, TEVA is hardly in the driver's seat.